GLAXO2,858.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹48,417 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)351.53351.74382.91382.91
Receivable Days (DSO)23.4728.4826.0826.08
Payable Days (DPO)418.72517.13477.20546.22
Cash Conversion Cycle (days)-43.72-136.91-68.21-137.23
Working Capital Turnover2.322.201.911.97
Asset Turnover0.970.910.880.88
Cash Conversion (CFO/Net Income)0.991.390.870.87
CFO/EBITDA0.641.100.690.69
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.